Liquid Biopsy

Currently, the ACTT project is available in Quebec, Ontario, Saskatchewan and British Columbia.

In Quebec, the collection service is provided by Genolife.

After receiving a test requisition from their oncologist, patients should contact Genolife to make an appointment for a blood drawn. Genolife can provide blood collection services across the province and will send the sample and documents directly to Canexia Health

The ACTT Project only accepts patients diagnosed with a relapse (suspected or known) or metastatic:

Patients can only be referred by their oncologist.

Please follow the instructions below:

The tests are performed at Canexia Health’s accredited clinical laboratory in Vancouver, British Columbia.

Canexia Health will provide the results to the ordering oncologist within 10 business days from the receipt of the blood sample.

FOLLOW IT is blood-based circulating tumor DNA (ctDNA) NGS multiplex panel that tests for 146 hotspots and 23 exons in 30 cancer genes that are known to be important in prognosis and treatment of multiple solid adult tumours. For the full gene list click here.

FOLLOW IT provides a detailed clinical report which includes interpretations of results, available clinical trials and current treatment options based on the molecular profile of the tumor. For a sample FOLLOW IT report, click here.

FOLLOW IT blood-based ctDNA test allows for a less invasive sampling than tissue biopsy, while providing the oncologist with genomic data. The genomic information provided may identify and help to select the most relevant targeted therapies for your patient. For a list of associated genes and treatments, click here.

FOLLOW IT is focused on actionable results, including biomarkers associated with response to FDA and Health Canada approved therapies, as well as current Canadian clinical trials. The FOLLOW IT report can help guide treatment options available to the patient that may not be accessible without this advanced molecular testing.